Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Predictors of Durable Remission After Successful Surgery for Cushing Disease: Results From the Multicenter RAPID Registry
Tenhoeve, Sam , Evans, James, Collopy, Sarah , Delery, William , Pacione, Donato , Silverstein, Julie , Gardner, Paul A. , Rotman, Lauren E., Yuen, Kevin C.J. , Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Benjamin, Carolina , Kshettry, Varun R. , Zada, Gabriel , Catalino, Michael P. , Little, Andrew S. , Karsy, Michael , Van Gompel, Jamie, Karsy, Michael , Findlay, Matthew C. , Alt, Jeremiah A. , Rennert, Robert C , Couldwell, William T. , Evans, James, Kim, Won Bae , Kim, Albert H. , Chicoine, Michael , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgery | June 21, 2024 | Volume: 95 | Issue: 4 | Pages: 761-769

10.1227/neu.0000000000003042 | PMID 39293794 Get It

BACKGROUND AND OBJECTIVE: Cushing disease (CD) affects mortality and quality of life along with limited long-term remission, underscoring the need to better identify recurrence risk. The identification of surgical or imaging predictors for CD remission after transsphenoidal surgery has yielded some inconsistent results and has been limited by single-center, single-surgeon, or meta-analyses studies. We sought to evaluate the multicenter Registry of Adenomas of the Pituitary and Related Disorders (RAPID) database of academic US pituitary centers to assess whether robust nonhormonal recurrence predictors could be elucidated. METHODS: Patients with treated CD from 2011 to 2023 were included. The perioperative and long-term characteristics of CD patients with and without recurrence were assessed using univariable and multivariable analyses. RESULTS: Of 383 patients with CD from 26 surgeons achieving postoperative remission, 288 (75.2%) maintained remission at last follow-up while 95 (24.8%) showed recurrence (median time to recurrence 9.99 ± 1.34 years). Patients with recurrence required longer postoperative hospital stays (5 ± 3 vs 4 ± 2 days, P = .002), had larger average tumor volumes (1.76 ± 2.53 cm 3 vs 0.49 ± 1.17 cm 3 , P = .0001), and more often previously failed prior treatment (31.1% vs 14.9%, P = .001) mostly being prior surgery. Multivariable hazard prediction models for tumor recurrence found younger age (odds ratio [OR] = 0.95, P = .002) and Knosp grade of 0 (OR = 0.09, reference Knosp grade 4, P = .03) to be protective against recurrence. Comparison of Knosp grade 0 to 2 vs 3 to 4 showed that lower grades had reduced risk of recurrence (OR = 0.27, P = .04). Other factors such as length of stay, surgeon experience, prior tumor treatment, and Knosp grades 1, 2, or 3 failed to reach levels of statistical significance in multivariable analysis. CONCLUSION: This multicenter study centers suggests that the strongest predictors of recurrence include tumor size/invasion and age. This insight can help with patient counseling and prognostication. Long-term follow-up is necessary for patients, and early treatment of small tumors may improve outcomes.
Liver disease and transplantation in telomere biology disorders: An international multicenter cohort
Kaj‐Carbaidwala, Batul , Lane, Adam , Agarwal, Suneet , Bertuch, Alison A. , Borovsky, Kristin A., Dufour, Carlo , Fioredda, Francesca , Giri, Neelam , Goldman, Frederick D. , Hertel, Paula M. , Keel, Sioḃán , Koura, Divya, Kratz, Christian P. , Liou, Iris, Nakano, Taizo A. , Nastasio, Silvia , Sasa, Ghadir , Miethke, Alexander , Penrice, Daniel D. , Wang, YunZu Michele , Beier, Fabian , Borovsky, Kristin A., Brennan, Steven K. , Calado, Rodrigo T. , Catto, Luiz Fernando Bazzo , Ebens, Christen L. , Gloude, Nicholas Joseph , Himes, Ryan , Kulkarni, Sakil S , Niewisch, Marena Rebekka , Savage, Sharon A. , Simonetto, Douglas A. , Ziegler, David Simon , Myers, Kasiani

Mayo Clinic

Hepatology Communications | June 19, 2024 | Volume: 8 | Issue: 7 | Pages: No page available

10.1097/hc9.0000000000000462 | PMID 38896081 Get It

Background: Patients with telomere biology disorders (TBD) develop hepatic disease, including hepatitis, cirrhosis, and hepatopulmonary syndrome. No specific treatment exists for TBD-related liver disease, and the role of liver transplantation (LT) remains controversial. Our study objectives were to describe the clinical characteristics, management, and outcomes in patients with TBD-related liver disease, and their LT outcomes. Methods: Data from 83 patients with TBD-associated liver disease were obtained from 17 participating centers in the Clinical Care Consortium of Telomere-Associated Ailments and by self-report for our retrospective, multicenter, international cohort study. Results: Group A (“Advanced”) included 40 patients with advanced liver disease. Of these, 20 underwent LT (Group A T ). Group M (“Mild”) included 43 patients not warranting LT evaluation, none of whom were felt to be medically unfit for liver transplantation. Supplemental oxygen requirement, pulmonary arteriovenous malformation, hepatopulmonary syndrome, and higher bilirubin and international normalized ratio values were associated with Group A. Other demographics, clinical manifestations, and laboratory findings were similar between groups. Six group A patients were declined for LT; 3 died on the waitlist. Median follow-up post-LT was 2.9 years (range 0.6–13.2 y). One-year survival post-LT was 73%. Median survival post-LT has not been reached. Group A T patients had improved survival by age compared to all nontransplant patients (log-rank test p = 0.02). Of 14 patients with pretransplant hypoxemia, 8 (57%) had improved oxygenation after transplant. Conclusions: LT recipients with TBD do not exhibit excessive posttransplant mortality, and LT improved respiratory status in 57%. A TBD diagnosis should not exclude LT consideration.
Impact of Obesity on Timing of Tracheotomy: A Multi‐institutional Retrospective Study
Yousef, Andrew , Soliman, Shady , Panuganti, Bharat , Francis, David O. , Klebaner, Dasha, Asturias, Alicia , Alattar, Ali , Wood, Samuel , Terry, M. C. , Bryson, Paul C. , Tipton, Courtney B. , Zhao, Elise E. , Maria, Chloe Santa , Sung, C. Kwang , Lao, Wilson P. , Thompson, Jordan M. , Crawley, Brianna K. , Rosen, Sarah P. , Berezovsky, Anna , Hennesy, Theresa B. , Joseph, Ian T. , Sarhadi, Kamron, Kuhn, Maggie A. , Abdel‐Aty, Yassmeen , Kennedy, Maeve M. , Weissbrod, Philip A. , Soliman, Shady I , Pang, John , Wood, Samuel , Terry, Morgan , O'Rourke, Ashli , Grimm, David R , Sung, C K , Crawley, Brianna K , Rosen, Sarah , Berezovsky, Anna , Clary, Matthew S , Abdel-Aty, Yassmeen, Lott, David G , Weissbrod, Philip A , Solomon, Isaac, Grimm, David R. , Kupfer, Robbi A. , Clary, Matthew S. , Lott, David G.

Mayo Clinic

The Laryngoscope | June 19, 2024 | Volume: 134 | Issue: 11 | Pages: 4674-4681

10.1002/lary.31586 | PMID 38895915 Get It

Objective To examine the impact of increased body mass index (BMI) on (1) tracheotomy timing and (2) short‐term surgical complications requiring a return to the operating room and 30‐day mortality utilizing data from the Multi‐Institutional Study on Tracheotomy (MIST). Methods A retrospective analysis of patients from the MIST database who underwent surgical or percutaneous tracheotomy between 2013 and 2016 at eight institutions was completed. Unadjusted and adjusted logistic regression analyses were used to assess the impact of obesity on tracheotomy timing and complications. Results Among the 3369 patients who underwent tracheotomy, 41.0% were obese and 21.6% were morbidly obese. BMI was associated with higher rates of prolonged intubation prior to tracheotomy accounting for comorbidities, indication for tracheotomy, institution, and type of tracheostomy ( p = 0.001). Morbidly obese patients (BMI ≥35 kg/m 2 ) experienced a longer duration of intubation compared with patients with a normal BMI (median days intubated [IQR 25%–75%]: 11.0 days [7–17 days] versus 9.0 days [5–14 days]; p < 0.001) but did not have statistically higher rates of return to the operating room within 30 days ( p = 0.12) or mortality ( p = 0.90) on multivariable analysis. This same finding of prolonged intubation was not seen in overweight, nonobese patients when compared with normal BMI patients (median days intubated [IQR 25%–75%]: 10.0 days [6–15 days] versus 10.0 days [6–15 days]; p = 0.36). Conclusion BMI was associated with increased duration of intubation prior to tracheotomy. Although morbidly obese patients had a longer duration of intubation, there were no differences in return to the operating room or mortality within 30 days. Level of Evidence 3 Laryngoscope , 134:4674–4681, 2024
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy
Moussa, Mohammad Jad , Khandelwal, Jaanki, Naik, Sagar A., Campbell, Matthew T. , Msaouel, Pavlos , Alhalabi, Omar , Singh, Parminder , Campbell, Matthew T , Msaouel, Pavlos , Alhalabi, Omar , Singh, Parminder , Wilson, Nathaniel R. , Naik, Sagar A. , Subbiah, Vivek , Singh, Parminder Pal

Mayo Clinic

Current Oncology | June 18, 2024 | Volume: 31 | Issue: 6 | Pages: 3342-3349

10.3390/curroncol31060254 | PMID 38920737 Get It

Small cell bladder cancer (SCBC) is a rare and aggressive disease, often treated with platinum/etoposide-based chemotherapy. Key molecular drivers include the inactivation of onco-suppressor genes (TP53, RB1) and amplifications in proto-oncogenes (MYC). We report a patient with SCBC who achieved an objective and prolonged response to lurbinectedin, which has been approved for metastatic small cell lung cancer, after developing disease progression on cisplatin/etoposide and nivolumab/ipilimumab. A genomic analysis of a metastatic biopsy prior to lurbinectedin initiation revealed a TP53 mutation and amplification of the cell cycle regulators E2F3 and MYCL. A repeat biopsy following the development of lurbinectedin resistance showed a new actionable ERBB2 alteration without significant change in the tumor mutation burden (six mutations/Mb). The present report suggests that lurbinectedin may be active and should be further explored in SCBC harboring TP53 mutations and amplifications in E2F3 and MYC family complexes.
Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.
Perez, Cesar A. , Hendrickson, Andrea E. Wahner , Orr, Douglas, Rojas‐Espaillat, Luis, Colón‐Otero, Gerardo , Reddick, Catherine W., Bayever, Eliel, Wee, Wen , Tolcher, Anthony W. , Murciano‐Goroff, Yonina R. , Anders, Carey K. , Hamilton, Erika , Swisher, Elizabeth M. , Mathews, Cara Amanda , Bashir, Babar , Adams, Gregory Paul

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS3173-TPS3173

10.1200/jco.2024.42.16_suppl.tps3173 Get It

TPS3173 Background: ELU001, pasifolate exatecan, is an ultra-small nanoparticle drug conjugate, known as a CDC (~6 nm), designed to target and penetrate into solid tumors. Due to its size, ELU001 exhibits rapid renal elimination which is expected to reduce or eliminate the toxicities associated with many antibody drug conjugates. ELU001 has ~13 folic acid targeting moieties and ~21 cathepsin-B cleavable exatecan topoisomerase-1 inhibitor payloads covalently bound to short polyethylene glycol chains surrounding a silica core, the C’Dot. ELU001 binds to cancer cells expressing FRα and is internalized into the lysosome where it releases the exatecan payload. ELU001’s dose escalation study reported at ESMO Congress 2023 (1), examined weekly, bi-weekly (Q2W), and tri-weekly schedules over a range of doses in 42 patients. The study revealed that ELU001 could be administered safely and identified a dose level and schedule for the Expansion Studies described below. 22 of the patients with ovarian or endometrial cancers had >1 post-baseline scan(s), of these 2 had a PR and 19 had SD by RECIST v1.1 criteria. ELU001 demonstrated activity against tumors across a range of FRα expression levels, from low to high, retrospectively assessed using the VENTANA FOLR1 RxDx assay and the PS2+ scoring system. Methods: The current multicenter, Tumor Group Expansion open-label phase 1/2 clinical trial investigates ELU001 in patients with ovarian and endometrial cancers and is enrolling three cohorts; 1) ovarian cancer with high FRα expression, 2) ovarian cancer with moderate and low expression and 3) endometrial cancer with low to high expression with assessments based upon the PS2+ scoring system (high = ≥ 75%, moderate = ≥ 50% to < 75%, low = 25% to < 50%, negative = <25% of tumor cells with 2+ or 3+ staining intensity). An initial exploratory dose of 2.0 mg/m2 Q2W was employed in all three cohorts and a second dose of 1.7 mg/m2 Q2W will be studied in the ovarian cancer cohorts. Patients will ultimately be randomized to one of two or more doses to optimize dosing for registration. Primary endpoint: Objective Response Rate (ORR); secondary endpoints include DOR, PFS, TFST, PFS2, OS, adverse events, PK, and ADA assessments. Approximately 20 patients per tumor group will be recruited in the U.S. 1. Ann. Oncol. (2023) 34 (suppl_2): S458-S497. Clinical trial information: NCT05001282 .
An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).
Patnaik, Amita , Azad, Nilofer S. , Bullock, Andrea J. , Davis, S. Lindsey , Goodwin, Rachel , Pelster, Meredith , Perez, Cesar A. , Pourhosseini, Pourya , Wang, Tianhua , Demers, Brigitte, Borad, Mitesh J. , Call, Justin , Fakih, Marwan , Lakhani, Nehal J. , Meric‐Bernstam, Funda

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS3160-TPS3160

10.1200/jco.2024.42.16_suppl.tps3160 Get It

TPS3160 Background: Patients (pts) with recurrent or metastatic solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), colorectal cancer (CRC), gastric adenocarcinoma (GC), and pancreatic ductal adenocarcinoma (PDAC), have limited treatment options with short PFS and OS despite recent advances (1-3). Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is highly expressed across multiple solid tumors, such as CRC, GC, PDAC, and NSCLC. Restricted normal tissue expression and efficient lysosomal trafficking of CEACAM5 highlight its potential as an anticancer target. SGN-CEACAM5C is a novel investigational antibody-drug conjugate (ADC) directed to CEACAM5 composed of the humanized immunoglobulin G (IgG1) anti-CEACAM5 monoclonal antibody tusamitamab chemically conjugated to 8 molecules of the topoisomerase 1 inhibitor 7-aminomethyl-10,11-methylenedioxycamptothecin (AMDCPT). SGN-CEACAM5C selectively binds to CEACAM5 present on the cell surface and is internalized via the endo-lysosomal pathway, with subsequent release of the payload through enzymatic cleavage. Release of the cytotoxic payload induces DNA damage, cell cycle arrest in S phase, and apoptosis in tumor cells. In vitro bystander activity was observed against tumor cells without CEACAM5 surface expression. SGN-CEACAM5C is highly active in multiple patient-derived xenograft models, including CRC, GC, and NSCLC, across various levels of CEACAM5 expression (4,5). These preclinical findings justify evaluation of SGN-CEACAM5C in a clinical trial setting. Methods: SGNCEA5C-001 (NCT06131840) is a phase 1, open-label, multicenter study designed to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of SGN-CEACAM5C in adults with select advanced solid tumors. This study consists of dose escalation (Part A), dose and schedule optimization (Part B), and dose expansion (Part C). Eligible pts are adults ≥18 years of age with confirmed metastatic or unresectable solid tumor malignancy, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, an ECOG PS of 0-1, and 1 of the following tumor types: CRC, GC/gastroesophageal junction adenocarcinoma (GEJ), PDAC, NSCLC (squamous/non-squamous), or SCLC. Primary endpoints include incidence of AEs, laboratory abnormalities, dose modifications due to AEs, dose-limiting toxicities, and cumulative safety. Secondary endpoints include estimates of PK parameters, incidence of antidrug antibodies, objective response rate and best response per RECIST v1.1 by investigator, duration of response, PFS, and OS. Safety and antitumor activity endpoints will be summarized using descriptive statistics. Recruitment is ongoing for Part A in North America. 1. Bordry 2021. 2. Chakrabarti 2022. 3. Merle 2022. 4. Baudat 2023. 5. Baudat 2024. Clinical trial information: NCT06131840 .
Multi‐center study on sellar reconstruction after endoscopic transsphenoidal pituitary surgery
Ali, Hawa M. , Leland, Evelyn M. , Stickney, Emily, Lohse, Christine M. , Iyoha, Ehiremen, Valappil, Benita, Filimonov, Andrey , Goetschel, Kaitlin , Young, Sarah C. , Shahin, Maryam N. , Sanusi, Olabisi , Sonfack, Davaine Joel Ndongo , Champagne, Pierre‐Olivier , Zwagerman, Nathan T. , Gardner, Paul A. , Zenonos, Georgios A. , Link, Michael J. , Peris‐Celda, Maria , Stokken, Janalee K., Stokken, Janalee K. , Wang, Eric W , Snyderman, Carl H , Van Gompel, Jamie, Choby, Garret , Carlson, Matthew L , Nadeau, Sylvie , Geltzeiler, Mathew , Gompel, Jamie J. Van , Choby, Garret , Pinheiro‐Neto, Carlos

Mayo Clinic

International Forum of Allergy & Rhinology | June 17, 2024 | Volume: 14 | Issue: 10 | Pages: 1558-1567

10.1002/alr.23382 | PMID 38884280 Get It

AbstractIntroductionSurgical techniques for sellar reconstruction include no reconstruction, use of synthetic materials, autologous grafts, and/or vascularized flaps. The aim of this study was to conduct a multi‐center study comparing the efficacy and postoperative morbidity associated with different sellar reconstruction techniques.MethodsA retrospective chart review of patients who underwent endoscopic transsphenoidal surgery for pituitary tumors from five participating sites between January 2021 and March 2023 was performed. The variables included demographics, tumor characteristics, reconstruction technique, postoperative cerebrospinal fluid leak (CSF) leak, and 22‐item Sino‐Nasal Outcome Test (SNOT‐22) scores. Comparisons of postoperative complications, SNOT‐22 scores, and duration of surgery by type of onlay reconstruction were evaluated using Fisher's exact test, analysis of variance, and Kruskal‒Wallis test.ResultsFive hundred and one patients were identified. The median tumor size was 2.1 cm, and 64% were non‐functioning. Intraoperative CSF leak was identified in 38% of patients. A total of 89% of patients underwent onlay reconstruction: 49% were reconstructed with mucosal grafts, 35% with nasoseptal flaps, and 5% with other onlay techniques. Nasoseptal flaps were utilized more frequently in the setting of giant pituitary adenomas (>3 cm), medial cavernous sinus wall resection, and high‐flow intraoperative CSF leaks. Cases who utilized mucosal grafts had an overall shorter operating time (median: 183 min vs. 240 min; p < 0.001). Five postoperative CSF leaks were identified, and therefore, statistical analysis could not be performed for this complication.ConclusionThe effectiveness and morbidity of different sellar reconstruction techniques are comparable. Vascularized flaps were utilized more frequently in the setting of larger tumors and high‐flow intraoperative CSF leaks.
Hepatitis B transmission/reactivation associated with Hepatitis B core antibody and Hepatitis C nucleic acid testing positive organs: A report from the Organ Procurement and Transplantation Network Disease Transmission Advisory Committee
Te, Helen S. , Lee, Dong Heun , Woolley, Ann E. , Fisher, Cynthia E. , Sellers, Marty T. , Taimur, Sarah , Livelli, Taylor, Watkins, T. I., Handarova, Dzhuliyana, Berry, Gerald J. , Graves, Riki, Hughart, Anna L., Kittleson, M. , Marboe, Charles C. , Miller, Rachel , Danziger‐Isakov, Lara , Abidi, Maheen Z , Taimur, Sarah , Berry, Gerald J , Trindade, Anil J , Pouch, Stephanie M , Danziger-Isakov, Lara , Te, Helen S , Abidi, Maheen Z. , Watkins, Tamika, Ho, Chak‐Sum , Sharma, Tanvi S. , Wood, R. Patrick, Zaffiri, Lorenzo , Pouch, Stephanie M.

Mayo Clinic

Transplant Infectious Disease | June 17, 2024 | Volume: 26 | Issue: S1 | Pages: No page available

10.1111/tid.14305 | PMID 38881210 Get It

AbstractBackgroundBetter access to direct‐acting antiviral (DAA) therapy has broadened the utilization of hepatitis C virus (HCV) nucleic acid testing (NAT) positive organs with excellent outcomes. However, DAA therapy has been associated with hepatitis B virus (HBV) reactivation.AimTo determine the risk of HBV transmission or reactivation with utilization of HBV core antibody positive (HBcAb+) and HCV NAT positive (HCV+) organs, which presumably required DAA therapy.MethodsThe number of HBcAb+ donors with delineated HCV NAT status was obtained from the Organ Procurement and Transplantation Network (OPTN) database. The number of unexpected HBV infections from transplanted organs adjudicated as “proven” or “probable” transmission was obtained from the OPTN Ad Hoc Disease Transmission Advisory Committee database. A chart review of the donors of “proven” or “probable” cases was conducted.ResultsFrom January 1, 2016, to December 31, 2021, 7735 organs were procured from 3767 HBcAb+ donors and transplanted into 7469 recipients; 545 (14.5%) donors were also HCV+. HBV transmission or reactivation occurred in seven recipients. The rate is not significantly different between recipients of HCV+ (0.18%, 2/1115) and the HCV NAT negative (HCV‐) organs (0.08%, 5/6354) (p = 0.28) or between recipients of HCV+ and HCV‐ livers as well as non‐liver organs. HBV transmission or reactivation occurred within a median of 319 (range, 41–1117) days post‐transplant in the setting of missing, inadequate, or truncated prophylaxis.ConclusionHBV reactivation associated with DAA therapy for HBcAb+ HCV+ organs is less frequent than reported in the non‐transplant population, possibly due to the common use of HBV prophylaxis in the at‐risk transplant population. image
Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease
Iyoha, Ehiremen, Jenkins, Sarah M. , Guo, Ruifeng , Iyoha, Ehiremen M, Guo, Ruifeng , Choby, Garret

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 17, 2024 | Volume: 171 | Issue: 4 | Pages: 1245-1249

10.1002/ohn.850 | PMID 38881402 Get It

AbstractSinonasal mucosal melanoma (SNMM) is a rare malignancy with poor prognosis and high recurrence rate. In those with recurrence, survival is dismal. Immunotherapy is an emerging area of investigation; however, there is a scarcity of data on immunotherapy outcomes in SNMM patients with recurrence. We report outcomes of immunotherapy in recurrent SNMM patients with distant versus nondistant recurrence. Fifty‐four patients with recurrent SNMM were identified, and 31 (57.4%) had distant recurrence. One‐year overall survival (OS) following recurrence was 47.5% (95% confidence interval [CI]: 34.0%‐60.9%), with a median survival of 2.8 years (95% CI: 2.0‐5.3). In those with distant recurrence, receipt of immunotherapy was associated with better OS compared to those without immunotherapy (hazard ratio [HR] = 0.29 [95% CI: 0.12‐0.68], P = .004). While patients with nondistant recurrence (n = 23), who received immunotherapy (n = 6) had worse OS compared to those who did not receive immunotherapy (HR = 4.76 [95% CI: 1.36, 15.89], P = .02).Level of EvidenceLevel IV.
Protocol for Improving Care by FAster risk-STratification through use of high sensitivity point-of-care troponin in patients presenting with possible acute coronary syndrome in the EmeRgency department (ICare-FASTER): a stepped-wedge cluster randomised qua
Pickering, John W. , Devlin, Gerard, Aldous, Sally, Jaffe, Allan S. , Apple, Fred S. , Kavsak, Peter A. , Cullen, Louise , Lord, Sarah J. , Joyce, Laura R , Frampton, Chris , Than, Martin , Lord, Sarah J , Joyce, Laura , Richards, Arthur M , Than, Martin , Cullen, Louise , Body, Richard , Jaffe, Allan S. , Mills, Nicholas L , Troughton, Richard W. , Peacock, William Frank , Lacey, Cameron James , Richards, Mark , Pitama, Suzanne G , Pickering, John W , Kavsak, Peter

Mayo Clinic

BMJ Open | June 13, 2024 | Volume: 14 | Issue: 6 | Pages: e083752

10.1136/bmjopen-2023-083752 | PMID 38871661 Get It

Introduction Clinical assessment in emergency departments (EDs) for possible acute myocardial infarction (AMI) requires at least one cardiac troponin (cTn) blood test. The turn-around time from blood draw to posting results in the clinical portal for central laboratory analysers is ~1–2 hours. New generation, high-sensitivity, point-of-care cardiac troponin I (POC-cTnI) assays use whole blood on a bedside (or near bedside) analyser that provides a rapid (8 min) result. This may expedite clinical decision-making and reduce length of stay. Our purpose is to determine if utilisation of a POC-cTnI testing reduces ED length of stay. We also aim to establish an optimised implementation process for the amended clinical pathway. Methods and analysis This quality improvement initiative has a pragmatic multihospital stepped-wedge cross-sectional cluster randomised design. Consecutive patients presenting to the ED with symptoms suggestive of possible AMI and having a cTn test will be included. Clusters (comprising one or two hospitals each) will change from their usual-care pathway to an amended pathway using POC-cTnI—the ‘intervention’. The dates of change will be randomised. Changes occur at 1 month intervals, with a minimum 2 month ‘run-in’ period. The intervention pathway will use a POC-cTnI measurement as an alternate to the laboratory-based cTn measurement. Clinical decision-making steps and logic will otherwise remain unchanged. The POC-cTnI is the Siemens (Erlangen Germany) Atellica VTLi high-sensitivity cTnI assay. The primary outcome is ED length of stay. The safety outcome is cardiac death or AMI within 30 days for patients discharged directly from the ED. Ethics and dissemination Ethics approval has been granted by the New Zealand Southern Health and Disability Ethics Committee, reference 21/STH/9. Results will be published in a peer-reviewed journal. Lay and academic presentations will be made. Māori-specific results will be disseminated to Māori stakeholders. Trial registration number ACTRN12619001189112.